SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
- PMID: 36173867
- DOI: 10.1093/eurheartj/ehac541
SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?
Conflict of interest statement
Conflict of interest : M.V. reports personal fees for speaker bureau and/or consulting in Advisory Board from Amarin, Amgen, Astra Zeneca, Kalos Medical, Menarini Int, Novartis Pharma, Novo Nordisk, outside the submitted work. D.P. has nothing to disclose.
Comment on
-
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27. N Engl J Med. 2022. PMID: 36027570 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical